[Formulation and antileukemic activity of quinolizidinylalkylaminic derivatives of naphthoquinone and anthraquinone].
By reacting three quinolizidinylalkylamines with 1,4-naphtoquinone, 2,3-dichloronaphto-1,4-quinone and 1-chloroanthraquinone nine compounds were obtained which are of interest as antitumoral, antiviral, antibacterial and antiparasitic agents. These compounds, so far, have been tested against lymphocytic leukemia P 388 in mice and found inactive.
Boido Canu
C
C
Boido
V
V
Sparatore
F
F
D000818:Animals; D000880:Anthraquinones / Q000138:chemical synthesis* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000138:chemical synthesis*; D055598:Chemical Phenomena; D002621:Chemistry; D007941:Leukemia P388 / Q000188:drug therapy*; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D008815:Mice, Inbred Strains; D009285:Naphthoquinones / Q000138:chemical synthesis* / Q000494:pharmacology; D011807:Quinolizines / Q000138:chemical synthesis* / Q000494:pharmacology
D000880:Anthraquinones; D000970:Antineoplastic Agents; D009285:Naphthoquinones; D011807:Quinolizines
Preparazione e attività antileucemica di derivati chinolizidinil alchilamminici del naftochinone e dell'antrachinone.